CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2014.
“This has been a period of tremendous momentum at Acceleron with the rapid progress and expansion of our clinical pipeline,” said John Knopf, Ph.D., Chief Executive Officer of Acceleron. “We presented encouraging interim clinical data from five different ongoing phase 2 clinical trials across all three of our clinical programs, in particular our hematology programs partnered with Celgene. These results illustrate the significant number of distinct opportunities in our pipeline to generate clinically and commercially promising therapies and we look forward to presenting additional exciting data at major medical conferences later this year.”
Help employers find you! Check out all the jobs and post your resume.
